Curemeta
Boston-based therapeutic oncology biotech focused on discovery and development of monoclonal antibodies and antibody-drug conjugates (ADCs) that target embryonic cancer-associated antigens present on aggressive and metastatic solid tumors. The company has a proprietary antibody-discovery platform, a pipeline of antibody candidates, a patent portfolio for multiple antibodies, and is preparing for IND-enabling studies and a Phase I clinical trial for a humanized ADC candidate targeting an embryonic tumor antigen.
Industries
Nr. of Employees
small (1-50)
Curemeta
Boston, Massachusetts, United States, North America
Patents
Podocalyxin and TRA-related antibody, methods of preparation and uses as an anti-cancer therapeutic agent
US-10509038-B2
View Details
Podocalyxin and TRA-related antibody, methods of preparation and uses as an anti-cancer therapeutic agent
US-10509038-B2
View DetailsProducts
Humanized IgG1 antibody candidate and corresponding ADC clinical candidate targeting an embryonic cancer-associated carbohydrate antigen
A humanized IgG1 antibody candidate specific to an embryonic cancer-associated carbohydrate antigen expressed on aggressive tumors, and a corresponding ADC created by conjugating the antibody to a cytotoxic payload (example payload referenced: mono-methyl auristatin E). Preclinical studies reported ADC internalization and tumor-cell killing in metastatic cancer models.
CM-09
CM-09 is an antibody-drug-conjugate cancer drug consisting of Bstrongximab, a human/mouse chimeric IgG1 antibody with high specificity and affinity to TRA-1-60, linked to the toxin Mono-Methyl Auristatin E. It is internalized into cancer cells where the toxin is released causing cell death, providing a highly specific targeted mechanism of action for difficult-to-treat cancers.
CM-14
A humanized IgG1 monoclonal antibody with high affinity and specificity to the cancer stem cell marker TRA-1-60, designed as a first-in-class humanized ADC for treating pancreatic and gastric cancers.
Bstrongximab
A therapeutic monoclonal antibody specific to the cancer target TRA-1-60, an embryonic target present in many cancers including gastric, prostate, and pancreatic cancer cells.
TRA-1-60
TRA-1-60 is a large carbohydrate molecule highly present on normal human embryonic stem cells during embryogenesis and is present on the cell surface of cancer cells in aggressive and metastatic tumors. It serves as an important tumor marker in many kinds of cancer, including metastatic gastric cancer.
Bstrazumab
A humanized IgG1 therapeutic antibody developed by CureMeta targeting cancer.
Humanized IgG1 antibody candidate and corresponding ADC clinical candidate targeting an embryonic cancer-associated carbohydrate antigen
A humanized IgG1 antibody candidate specific to an embryonic cancer-associated carbohydrate antigen expressed on aggressive tumors, and a corresponding ADC created by conjugating the antibody to a cytotoxic payload (example payload referenced: mono-methyl auristatin E). Preclinical studies reported ADC internalization and tumor-cell killing in metastatic cancer models.
CM-09
CM-09 is an antibody-drug-conjugate cancer drug consisting of Bstrongximab, a human/mouse chimeric IgG1 antibody with high specificity and affinity to TRA-1-60, linked to the toxin Mono-Methyl Auristatin E. It is internalized into cancer cells where the toxin is released causing cell death, providing a highly specific targeted mechanism of action for difficult-to-treat cancers.
CM-14
A humanized IgG1 monoclonal antibody with high affinity and specificity to the cancer stem cell marker TRA-1-60, designed as a first-in-class humanized ADC for treating pancreatic and gastric cancers.
Bstrongximab
A therapeutic monoclonal antibody specific to the cancer target TRA-1-60, an embryonic target present in many cancers including gastric, prostate, and pancreatic cancer cells.
TRA-1-60
TRA-1-60 is a large carbohydrate molecule highly present on normal human embryonic stem cells during embryogenesis and is present on the cell surface of cancer cells in aggressive and metastatic tumors. It serves as an important tumor marker in many kinds of cancer, including metastatic gastric cancer.
Bstrazumab
A humanized IgG1 therapeutic antibody developed by CureMeta targeting cancer.
Services
Seeking investors and development partners to support clinical and development activities.
Seeking investors and development partners to support clinical and development activities.
Expertise Areas
- Antibody discovery and engineering
- Antibody-drug conjugate (ADC) development
- Target identification and validation for embryonic cancer markers
- Preclinical in vivo efficacy studies
Key Technologies
- Monoclonal antibody generation
- Antibody humanization
- Antibody-drug conjugation
- In vivo metastatic cancer models
News & Updates
Completion of humanization of the lead IgG1 antibody candidate (humanized IgG1 reported to retain binding and biophysical characteristics).
Planned timeline to begin IND-enabling studies and file an IND with the FDA between January 2025 and June 2026.
Planned start of a Phase I clinical study for pancreatic and gastric cancer patients and continued advancement of the antibody pipeline.
Publication describing use of a TRA-1-60-specific antibody-drug conjugate in a metastatic gastric cancer mouse model with reported therapeutic impact in advanced-stage gastric cancers.
A US patent was received (2019) on the lead therapeutic monoclonal antibody specific to an embryonic cancer target referenced on the site.
Reported filing of patents on 11 antibodies specific to human cancers and not found in normal tissues.
Completion of humanization of the lead IgG1 antibody candidate (humanized IgG1 reported to retain binding and biophysical characteristics).
Planned timeline to begin IND-enabling studies and file an IND with the FDA between January 2025 and June 2026.
Planned start of a Phase I clinical study for pancreatic and gastric cancer patients and continued advancement of the antibody pipeline.
Publication describing use of a TRA-1-60-specific antibody-drug conjugate in a metastatic gastric cancer mouse model with reported therapeutic impact in advanced-stage gastric cancers.
A US patent was received (2019) on the lead therapeutic monoclonal antibody specific to an embryonic cancer target referenced on the site.
Reported filing of patents on 11 antibodies specific to human cancers and not found in normal tissues.